Leerink raised the firm’s price target on Insmed (INSM) to $115 from $100 and keeps an Outperform rating on the shares. The firm notes Insmed reported Phase 2b PAH data with TPIP that exceeded all expectations, with a statistically significant and clinically meaningful 6MWD benefit. Leerink remains positive on the stock ahead of the brensocatib launch later this summer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Morning Movers: Insmed jumps, United Therapeutics falls after TPIP study results
- Liquidia falls after Insmed’s TPIP meets endpoints in study
- United Therapeutics falls after Insmed’s TPIP meets endpoints in study
- Insmed Announces Positive Phase 2b Study Results
- Insmed’s Inhalation Powder meets endpoints in Phase 2b PAH trial